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Abstract
Background: Viral respiratory infections are common worldwide and range from completely benign disease to life-
threatening illness. Symptoms can be unspecific, and an etiologic diagnosis is rarely established because of a lack
of suitable diagnostic tools. Improper use of antibiotics is common in this setting, which is detrimental in light of
the development of bacterial resistance. It has been suggested that the use of diagnostic tests could reduce
antibiotic prescription rates. The objective of this study was to evaluate whether access to a multiplex polymerase
chain reaction (PCR) assay panel for etiologic diagnosis of acute respiratory tract infections (ARTIs) would have an
impact on antibiotic prescription rate in primary care clinical settings.
Methods: Adult patients with symptoms of ARTI were prospectively included. Nasopharyngeal and throat swabs
were analysed by using a multiplex real-time PCR method targeting thirteen viruses and two bacteria. Patients
were recruited at 12 outpatient units from October 2006 through April 2009, and samples were collected on the
day of inclusion (initial visit) and after 10 days (follow-up visit). Patients were randomised in an open-label
treatment protocol to receive a rapid or delayed result (on the following day or after eight to twelve days). The
primary outcome measure was the antibiotic prescription rate at the initial visit, and the secondary outcome was
the total antibiotic prescription rate during the study period.
Results: A total sample of 447 patients was randomised. Forty-one were excluded, leaving 406 patients for analysis.
In the group of patients randomised for a rapid result, 4.5% (9 of 202) of patients received antibiotics at the initial
visit, compared to 12.3% (25 of 204) (P = 0.005) of patients in the delayed result group. At follow-up, there was no
significant difference between the groups: 13.9% (28 of 202) in the rapid result group and 17.2% (35 of 204) in the
delayed result group (P = 0.359), respectively.
Conclusions: Access to a rapid method for etiologic diagnosis of ARTIs may reduce antibiotic prescription rates at
the initial visit in an outpatient setting. To sustain this effect, however, it seems necessary to better define how to
follow and manage the patient according to the result of the test, which warrants further investigation.
Trial registration: ClinicalTrials.gov identifier: NCT01133782.
Background
Acute respiratory tract infections (ARTIs) represent a
major global health burden [1], and viruses cause a large
proportion of ARTIs. Distinguishing bacterial ARTIs
that require antibiotic treatment from viral ARTIs not
needing an antibiotic prescription can be difficult on
clinical grounds alone and causes unnecessary use of
antibiotics, with the highest rates occurring in the pri-
mary care setting [2,3]. Excess use of antibiotics has
major implications for health economics and, more
importantly, for the development of bacterial resistance
[3,4], as well as for the individual patient in terms of
adverse events such as allergic reactions and antibiotic-
associated diarrhoea [5,6]. The predictive value of vital
signs, C-reactive protein (CRP) and X-ray findings for
diagnosing pneumonia requiring antibiotics is low [7,8].
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tive example of the unnecessary use of antibiotics,
where the recommended therapy for immune competent
adults does not include antibiotic treatment [9,10], yet
antibiotics were found to have been prescribed for this
condition at high rates in studies conducted in the Uni-
ted Kingdom (64%) [11], Sweden (50% to 60%) [12,13]
and the United States (59%) [14].
The use of improved diagnostic methods such as
nucleic acid amplification tests (NAATs), including mul-
tiplex real-time polymerase chain reaction (RT-PCR)
assays, has increased in recent years. These methods
have proven to be equivalent or superior to conven-
tional methods [15-19] and to have a short turnaround
time at the laboratory, as well as affording clinicians the
ability to analyse several respiratory agents within the
same patient sample.
It has been suggested that the use of NAATs, includ-
ing multiplex PCR methods, for the detection of respira-
tory pathogens could reduce antibiotic prescription rates
[14,18]. The present study was designed to evaluate
whether access to a multiplex RT-PCR method targeting
thirteen viruses would have an impact on antibiotic pre-
scription rates for ARTI in a primary care setting.
Methods
Study design
We conducted an investigator-initiated, multicentre,
prospective, randomised, controlled trial with adult
patients in a primary care setting. Eligibility criteria for
participants were age ≥ 18 years and a diagnosis of com-
munity-acquired ARTI, defined as having a history of at
least two of the following symptoms: coryza/nasal con-
gestion/sneezing, sore throat/odynophagia, cough,
pleuritic chest pain, shortness of breath or fever for
which the physician found no other explanation, with a
duration of less than 14 days. Exclusion criteria included
confirmed bacterial infection (defined as a positive
Streptococcus group A quick test and clinical findings
corresponding to bacterial tonsillitis, perforated acute
otitis media, high suspicion of lobar pneumococcal
pneumonia or severe septicaemia, a positive blood cul-
ture for a clinically significant bacterial pathogen and
clinical findings corresponding to septicaemia) and
ongoing antibiotic treatment. Patients were recruited at
12 outpatient units (eight primary healthcare centres
and four departments of infectious diseases), and sam-
ples were collected from October 2006 through April
2009. Signs and symptoms were recorded in a web-
based case report form.
Randomisation and masking
Patients were enrolled by the treating physician on the
day of inclusion and stratified according to duration of
symptoms of either ≤5 days or > 5 days. Open-label
(nonblinded) randomisation (ratio 1:1) was performed
by means of a predefined list and using a concealed,
central, web-based procedure on the day of inclusion for
the treating physician to receive the results from the
multiplex PCR analysis either on the day following
inclusion (the rapid result cohort) or eight to twelve
days later (the delayed result cohort).
Recruitment was performed from Sunday through
Thursday from 8 AM until 5 PM, allowing for the labora-
tory to report results the following day. Nasopharyngeal
(flocked nylon swabs; Microrheologics, Brescia, Italy) and
throat swab specimens were collected from each patient.
The swabs were jointly placed in a sterile container with
1 mL of sodium chloride solution and sent to the labora-
tory the same day. Specimens were either analyzed
directly or frozen at -70°C for delayed analysis (see ran-
domisation and masking above). The results were com-
municated through the web-based case report form to a
study nurse at each site. Additional diagnostic testing,
including throat and sputum cultures, CRP and X-ray
investigations, were left to the discretion of the treating
physician and recorded in the case report form.
Outcome measures
The objective of the study was to evaluate whether
access to a rapid etiologic diagnostic method would
have an impact on antibiotic prescription. The primary
outcome measure was the antibiotic prescription rate at
the initial visit (or within 48 hours thereafter), and the
secondary outcome measure was the total antibiotic pre-
scription rate during the study period. Antibiotic pre-
scription at the initial visit (or within 48 hours
thereafter) was recorded and analysed in relation to
access to a rapid vs. a delayed result. Results in the
rapid result group were provided to the treating physi-
cian within 24 hours for the majority of patients and
within 48 hours for all patients. The final management
of all patients and how to act upon the given result of
the PCR assay were left to the discretion of the treating
physician. All patients were asked to return for a follow-
up visit eight to twelve days after the initial visit, and
this time period represents the duration of follow-up in
the study. The total antibiotic prescription rate (pre-
scriptions at initial visit, atf o l l o w - u pv i s i to rb e t w e e n
those visits) was recorded and constituted the secondary
outcome measure in the study. The prescription of anti-
viral medications was not recorded. Serious adverse
events (SAEs) were defined as death, life-threatening
events, hospitalisation or events resulting or threatening
to result in persistent or significant disability. The
Regional Ethical Review board approved the study, and
all patients provided written informed consent to parti-
cipate in the study.
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We utilized a RT-PCR procedure based on automated
specimen extraction and multiplex amplification
adapted for respiratory specimens as previously
described [20]. Briefly, nucleic acid from 100 μLo ft h e
respiratory specimen was extracted into an elution
volume of 100 μLb yu s i n gaM a g n a p u r eL Cr o b o t
(Roche Molecular Systems, Mannheim, Germany)
according to the total nucleic acid protocol and was
amplified in an ABI 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA) in 50-μL
reaction volumes. After a reverse transcription step, 45
cycles of two-step PCR were performed. Each sample
was amplified in six parallel reactions containing pri-
m e r sa n dp r o b e sa sp r e v i o u s l yr e p o r t e d[ 2 0 ] ,w i t ht h e
modification of adenovirus being analysed in a separate
reaction. Included in the panel were parainfluenzavirus
(PIV) types 1 through 3, influenza virus A (IfA) and
influenza virus B (IfB), human metapneumovirus,
respiratory syncytial virus (RSV), human rhinovirus
(hRV), enterovirus (EV), adenovirus (AdV) and human
coronavirus (hCoV) types 229E, OC43 and NL63, along
with the bacteria Mycoplasma pneumoniae and Chlamy-
dophila pneumoniae.
The primers and probes of all RT-PCR assays were
designed to bind conserved segments of the targeted
agents. This is particularly important for AdV, hRV and
EV, which are characterised by a large number of sub-
types. The accuracy of the AdV PCR assay has been
documented by Heim et al.[ 2 1 ] .T h et a r g e tr e g i o nf o r
the hRV and EV assays was the conserved segment of
the 5’ untranslated region that allows amplification of all
subtypes and which has been used previously by others
[22-24]. The primers and probes used for IfB and PIV
type 3 were developed by Dr Lars Nielsen, Copenhagen,
Denmark; those for PIV types 1 and 2 were previously
described by Watzinger et al. [22]; those for hCoV
(types NL63, 229E and OC43) were described previously
by Gunson et al. [24]; and those for IfA virus were a
modification of a system published by Ward et al. [25].
Statistical analysis
On the basis of the nature of the primary outcome mea-
sure, patients with protocol violations and/or missing
data were excluded from the primary analysis. This was
predefined in the analysis plan. The c
2 test was used to
compare proportions. P < 0.05 was considered statisti-
cally significant. The study was scheduled to include at
least 200 patients in each group, allowing for a statistical
power of 80% to demonstrate an estimated reduction in
antibiotic prescription rate from 20% to 10% in the
rapid result group. Multivariate analysis using backward
stepwise (Wald test) logistic regression was carried out
to analyse factors separately and independently to
predict a positive PCR result as well as the prescription
of antibiotics. SPSS version 17.0 for Macintosh software
(SPSS Inc, Chicago, IL, USA) was used for all statistical
analyses.
Results
Study design and baseline characteristics
The patient flow according to the study design is shown
in Figure 1. The baseline characteristics of the two
groups of patients randomised for rapid vs. delayed
results are shown in Table 1.
Primary outcome measure
In the entire study population, antibiotics were pre-
scribed for 8.4% (34 of 406) of patients at the initial visit
(or within 48 hours thereof). In the group of patients
randomised for a rapid result, 4.5% (9 of 202) of patients
received an antibiotic, compared to 12.3% (25 of 204) of
patients in the delayed PCR-based result group (P =
0.005) (see Table 2). Patients with symptom duration ≤
5 days in the rapid result group received significantly
fewer antibiotic prescriptions than patients in the
delayed result group.
Of the 34 patients who received initial antibiotic treat-
ment, 14 (41%) tested positive for a respiratory virus,
comprising three in the rapid result group and eleven in
the delayed result group (see Table 2).
Secondary outcome measure
A total of 335 (83%) of 406 patients returned for the
optional follow-up visit or were available for a telephone
appointment (visit, n = 243; telephone appointment, n =
92), comprising 166 (82%) of 202 patients in the rapid
result group and 169 (83%) of 204 patients in the
delayed result group. In total, 28 patients (13.9%) in the
rapid result group and 35 patients (17.2%) in the delayed
result group received antibiotic treatment at either the
initial or follow-up visit. This difference was not statisti-
cally significant (P = 0.359). Antibiotic prescriptions out-
side the study (that is, by other than the study
physician) were allowed. At the follow-up visit, two
(11%) of nineteen patients in the rapid result group and
one (11%) of nine patients in the delayed result group
reported ongoing antibiotic treatment prescribed outside
the study. The investigators reported no SAEs.
Aetiology
As shown in Table 3, 191 patients (47%) tested positive
for one agent on the basis of a multiplex PCR assay per-
formed at the initial visit. In addition, 12 patients (5.9%)
tested positive for two agents in the same sample. In
three of these patients, one virus and one bacterium
were detected, and in nine patients, two viruses were
detected (see Table 4).
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CRP levels were recorded in 301 (74%) of 406 patients,
and a predefined subgroup analysis revealed that 39
patients (13%) had a CRP level ≥50 mg/L and that 15
patients (5%) had a CRP level > 100 mg/L. Of the 39
patients with a CRP level ≥50 mg/L, 12 patients (31%)
received antibiotic treatment at the initial visit,
compared to 17 (7%) of 262 patients in the group with a
CRP level < 50 mg/L (P < 0.0001). In the rapid result
group, two (8%) of twenty-four patients with a CRP
level ≥50 mg/L received antibiotics, compared to 10
(67%) of 15 patients in the delayed result group (P =
0.0001). Patients who tested positive for Mycoplasma
pneumoniae or Chlamydophila pneumoniae were
453Screenedforinclusion
6Excluded
2D i f 2 k 2Durationofsymptoms>2weeks
1Lessthan18yearsofage
1Hospitalacquiredinfection
2Withdrawalofconsent
227 Randomised to rapid result 220 Randomised to delayed result
447Randomised
227Randomisedtorapidresult 220Randomisedtodelayedresult
0Withdrawalofconsent
1Confirmedbacterialinfection
6Ongoingantibiotictreatment
1Withdrawalofconsent
2Confirmedbacterialinfection
5Ongoingantibiotictreatment gg
0Durationofsymptoms>2weeks
0Incorrectsampling
9Delayedtransporttolaboratory
gg
2Durationofsymptoms>2weeks
2Incorrectsampling
13Delayedtransporttolaboratory
202 Includedinanalysisofprimary
endpoint
204 Includedinanalysisofprimary
endpoint
36LosttofollowͲupatday10+/– 2 35LosttofollowͲupatday10+/– 2
166Includedinanalysisofsecondary
endpoint
169Includedinanalysisofsecondary
endpoint
Figure 1 Flowchart of patients.
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for M. pneumoniae, available for five of seven patients,
ranged from 58 mg/L to 210 mg/L, and the CRP level
was 35 mg/L for the only patient who tested positive for
C. pneumoniae). A virus (M. pneumoniae and C. pneu-
moniae excluded) was found in 49% of patients (19 of
39) with a CRP level ≥50 mg/L and in 27% of patients
(4 of 15) with a CRP level ≥100 mg/L.
Table 1 Baseline characteristics of patients with acute respiratory tract infection openly randomised to rapid (within
24 to 48 hours) or delayed (after eight to twelve days) multiplex PCR assay results
a
Variable Rapid analysis group (n = 202) Delayed analysis group (n = 204)
Demographics
Median age, yr (IQR) 39 (31 to 50) 39 (31 to 53)
Male sex, n (%) 79 (39.1) 90 (44.1)
Coexisting illnesses
b, n (%)
Patients with available data 120 (59.4) 109 (53.4)
No reported coexisting illness 77 (64.2
c) 68 (62.4
d)
Asthma 14 (11.7
c) 11 (10.1
d)
COPD 2 (1.7
c)-
Allergies 6 (5.0
c) 10 (9.2
d)
Diabetes 2 (1.7
c) 1 (0.9
d)
Neoplastic disease 1 (0.8
c) 2 (1.8
d)
Autoimmune disease
e 3 (2.5
c) 4 (3.7
d)
Ischaemic heart disease/angina 2 (1.7
c) 1 (0.9
d)
Clinical findings
Median duration of symptoms, days (IQR) 5 (3 to 7) 5 (3 to 9)
Median body temperature, °C (IQR) 37.1 (36.6 to 37.5) 36.9 (36.6 to 37.4)
Body temperature ≥38.5°C, n (%) 6 (3.0
f) 12 (6.0
g)
Median heart rate, beats/minute (IQR) 76 (67 to 88) 78 (70 to 87)
Tachycardia
h, n (%) 19 (9.4) 18 (8.8)
Median respiratory rate, breaths/min (IQR) 16 (14 to 19) 16 (14 to 19)
Hypoxia
i, n (%) 9 (4.5) 8 (3.9)
Laboratory findings
CRP < 50 mg/L, n (%) 122 (83.6
j) 140 (90.3
k)
CRP ≥50 mg/L, n (%) 24 (16.4
j) 15 (9.7
k)
Symptoms, n (%)
Coryza 167 (82.7) 171 (83.8)
Sore throat 153 (75.7) 157 (77.0)
Headache 149 (74.1) 149 (73.0)
Dry cough 130 (67.0) 132 (67.0)
Productive cough 120 (59.4) 108 (52.9)
Shortness of breath 111 (55.0) 113 (55.4)
Fever 106 (52.7) 109 (53.4)
Myalgia 107 (53.0) 100 (49.0)
Red eyes 83 (41.1) 81 (39.9)
Joint pain 83 (41.1) 79 (38.7)
Chest pain 53 (26.2) 40 (19.6)
Diarrhoea 17 (8.4) 21 (10.3)
Vomiting 10 (5.0) 16 (7.8)
Rash 10 (5.0) 13 (6.4)
aIQR, interquartile range; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein;
bcoexisting illnesses are those likely to influence the decision
whether to prescribe antibiotics; conditions not included were fibromyalgia, lumbago, adenoids, migraine, depression, Parkinson’s disease, hypothyroidism,
osteoarthritis, Gilbert’s syndrome, psoriasis, bradycardia, hepatitis C virus, scoliosis and pregnancy;
cnumber of patients with data for coexisting illness, rapid
analysis group (n = 120);
dnumber of patients with data for coexisting illness, delayed analysis group (n = 109);
eautoimmune diseases included inflammatory
bowel syndrome (Crohn’s disease, ulcerative colitis), systemic lupus erythematosus, rheumatoid arthritis, polymyalgia rheumatica and multiple sclerosis;
fnumber
of patients tested for body temperature, rapid analysis group (n = 198);
gnumber of patients tested for body temperature, delayed analysis group (n = 201);
htachycardia defined as heart rate ≥100 beats/minute;
ihypoxia defined as pulse oximetry < 95%;
jnumber of patients tested for CRP, rapid analysis group (n =
146);
knumber of patients tested for CRP, delayed analysis group (n = 155).
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In multivariate analysis of recorded symptoms, fever
(odds ratio (OR) 1.98, 95% confidence interval (95% CI)
1.30 to 3.03, P = 0.002) and pleuritic chest pain (OR
1.72, 95% CI 1.04 to 2.86, P = 0.04) remained indepen-
dently predictive of a positive PCR result (with M. pneu-
moniae and C. pneumoniae excluded from the analysis).
A reported sore throat (OR 0.60, 95% CI 0.37 to 0.97, P
= 0.04) was significantly more common among patients
with a negative PCR result.
Vomiting remained the only symptom associated
with the prescription of antibiotics at the initial visit
(OR 5.91, 95% CI 2.20 to 15.85, P = 0.0004) in multi-
variate analysis. High fever (≥38.5°C) was more
Table 2 Antibiotic prescription at initial visit (and within 48 hours of initial visit) for adult patients with acute
respiratory tract infection, according to randomisation group (rapid result vs. delayed result)
Antibiotic prescription Rapid result (n = 202) Delayed result (n = 204) P
Initial antibiotic treatment, n (%) 9 (4.5) 25 (12.3) 0.005
a
At initial visit 7 (3.5) 21 (10.3)
After 24 to 48 hours 2 (1.0) 4 (2.0)
b-lactam
b 4 (2.0) 13 (6.4) -
Tetracycline 4 (2.0) 8 (3.9) -
Macrolide 1 (0.5) 3 (1.5) -
Quinolone - 1 (0.5) -
Patient demographics at initial antibiotic treatment, n (%)
Body temperature ≥38.5°C, n (%) - 4 (33.3
c)-
CRP level ≥50 mg/L, n (%) 2 (8.3
d) 10 (67.0
e) < 0.001
a
Duration of illness ≤5 days, n (%) 3 (3.3
f) 12 (12.4
f) 0.02
a
Duration of illness > 5 days, n (%) 6 (5.4) 13 (12.1) -
Patients with virus detected, n (%) 91 (45.0) 91 (44.6) -
Antibiotics prescribed 3 (3.3
g) 11 (12.1
g) 0.03
a
Patients with Mycoplasma pneumoniae detected, n (%) 5 (2.5) 2 (1.0) -
Antibiotics prescribed, n 2
h 2
h
Patients with Chlamydophila pneumoniae detected, n (%) 1 (0.5) -
Antibiotics prescribed, n 1
i --
ac
2 test;
bphenoxymethylpenicillin or amoxicillin with or without clavulanic acid or loracarbef;
cfour (33.3%) of twelve patients;
dtwo (8.3%) of twenty-four
patients;
e10 (67.0%) of 15 patients;
fthree (3.3%) of ninety-one patients and 12 (12.4%) of 97 patients, respectively;
gthree (3.3%) of ninety-one patients and 11
(12.1%) of 91 patients, respectively;
hone patient received antibiotics within 24 hours and the other within 48 hours in each group, for a total of two patients in
each group as indicated in table;
ipatient received antibiotics within 48 hours.
Table 3 Results (multiple detections not included) of multiplex real-time polymerase chain reaction assays of all
included patients in order of frequency and by randomisation group (rapid vs. delayed result group)
Detected pathogens All patients, n (%) Rapid result group, n (%) Delayed result group, n (%)
Influenza A virus 56 (13.8) 31 (15.3) 25 (12.3)
Rhinovirus 40 (9.9) 24 (11.9) 16 (7.8)
Coronavirus (all subtypes) 29 (7.1) 11 (5.4) 18 (8.8)
Coronavirus OC43 16 (3.9) 4 (2.0) 12 (5.9)
Coronavirus NL63 11 (2.7) 5 (2.5) 6 (2.9)
Coronavirus 229E 2 (0.5) 2 (1.0) -
Respiratory syncytial virus 18 (4.4) 6 (3.0) 12 (5.9)
Influenza B virus 14 (3.4) 7 (3.5) 7 (3.4)
Metapneumovirus 14 (3.4) 6 (3.0) 8 (3.9)
Parainfluenzavirus types 1 through 3 7 (1.7) 4 (2.0) 3 (1.5)
Mycoplasma pneumoniae 7 (1.7) 5 (2.5) 2 (1.0)
Adenovirus 4 (1.0) 2 (1.0) 2 (1.0)
Enterovirus 1 (0.2) - 1 (0.5)
Chlamydophila pneumoniae 1 (0.2) 1 (0.5) -
No pathogen found 215 (53.0) 105 (52.0) 110 (54)
Total, N (%) 406 (100) 202 (100) 204 (100)
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delayed result (12 of 201 patients; 6.0%) than in the
group randomised for a rapid result (6 of 198; 3.0%)
(see Table 1), but no significant difference in the num-
ber of antibiotic prescriptions at the initial visit for
these groups was noted (see Table 2).
Discussion
We have shown that access to a rapid result using a
method for aetiologic diagnosis of ARTIs in an outpati-
ent setting significantly reduced antibiotic prescriptions
at the initial visit. However, this effect was no longer
significant at the time of follow-up. In our study, we
evaluated the impact of access to a rapid diagnostic tool
rather than the impact of the actual test result, which
implies that the mere prospect of a rapid aetiologic
diagnosis can influence therapeutic decisions made for
patients with an indistinct clinical presentation.
In the subgroup of patients with a CRP level ≥50
m g / L ,t h i se f f e c tw a se v e nm o r ep r o n o u n c e d .A m o n g
patients with positive PCR results for viruses, signifi-
cantly fewer patients in the rapid result group received
antibiotics than in the delayed result group. Our
results are in line with the reduction of antibiotic pre-
scriptions when rapid diagnostic tests for IfA virus
were used systematically for hospitalised adult patients
[26] and children [27], although these studies evaluated
the impact of the result of the test and thus are not
fully comparable.
The limitations of this study include the choice of
antibiotic prescription as the primary outcome and its
open-label design, which might have led to performance
bias; that is, the physicians might have been influenced
by the randomisation in making the decision whether to
prescribe antibiotics. Also, on the basis of the study
design with an optional follow-up visit, a large number
of patients were lost to follow-up, and because of the
relatively short follow-up period, the effect and duration
of antibiotic treatment in relation to the diagnosis could
not be properly evaluated. To influence antibiotic resis-
tance and adverse events following antibiotic therapy, it
is necessary to reduce the total rate of antibiotic pre-
scriptions, which was not achieved in our study. How-
ever, at the time of planning for the study, limited
prospective data were available on the performance of a
multiplex PCR panel for the diagnosis of viral and bac-
terial ARTIs in clinical practise. It was not possible to
define whether patients should be prescribed an antibio-
tic depending on the test result. We therefore chose
antibiotic prescriptions at the initial visit as a straight-
forward primary outcome measure to evaluate whether
access to the test would have any effect on antibiotic
prescription rates, and this should be included in future
studies of algorithms for the management of patients
with ARTIs.
Systematic testing for bacterial pathogens such as
Streptococcus pneumoniae, Haemophilus influenzae and
Moraxella catarrhalis was not conducted in this study.
These bacteria may act as potential respiratory patho-
gens (PRPs) harbouring in the upper respiratory tract,
and an extension of the panel to include these bacterial
agents might improve the clinical utility of the test.
However, the interpretation of the detection of bacterial
pathogens in nasopharyngeal samples in heterogeneous
syndromes such as ARTIs is unclear. Cultured S. pneu-
moniae from the nasopharynx of adults has been shown
Table 4 Codetection of agents in multiplex real-time polymerase chain reaction assays from the same
nasopharyngeal/oropharyngeal sample at initial visit of adults with ARTI
a by randomisation group (rapid result vs.
delayed result)
Agent 1 Agent 2 Ct value
b (agent 1/agent 2)
Rapid result group
Rhinovirus Influenza A virus 24/41
Rhinovirus Respiratory syncytial virus 33/34
Rhinovirus Mycoplasma pneumoniae 24/30
Mycoplasma pneumoniae Rhinovirus 34/36
Mycoplasma pneumoniae Coronavirus OC43 28/35
Adenovirus Rhinovirus 20/35
Influenza B virus Rhinovirus 36/38
Metapneumovirus Rhinovirus 37/42
Parainfluenzavirus Respiratory syncytial virus 28/30
Delayed result group
Influenza A virus Coronavirus OC43 29/31
Influenza B virus Rhinovirus 31/37
Respiratory syncytial virus Rhinovirus 31/36
aARTI, acute respiratory tract infection;
bCt value, cycle threshold value.
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nosis of pneumococcal pneumonia [28]. PCR-based
detection of S. pneumoniae from the oropharynx and
nasopharynx without codetection of other commensal
Streptococcus spp. poses technical difficulties.
Lieberman et al. [29] reported higher sensitivity in
using nasopharyngeal washing compared to nasopharyn-
geal swabs in the detection of PRPs. To keep sampling
simple, nasopharyngeal washing was not used in this
study, which may constitute a study limitation. However,
we used flocked nasopharyngeal swabs, which probably
yield higher detection rates than previously reported in
studies in which cotton-tipped nasopharyngeal swabs
were used [30]. The study population consisted of
patients with a broad spectrum of clinical manifesta-
tions, many of whom had mild symptoms. However,
since the prescription of antibiotics for these patients is
not uncommon, this was a deliberate study design.
Previously, Oosterheert et al.[ 1 8 ]i n v e s t i g a t e dt h e
impact of a PCR method for aetiologic diagnosis of
lower RTIs in adults but failed to show any reduction in
the use of antibiotics. However, their study included
only hospitalised patients, and the end point was to reg-
ister a change of ongoing treatment regimen rather than
whether to make the initial decision to prescribe anti-
biotic treatment.
At follow-up, our study no longer showed any signifi-
cant difference in antibiotic use between the two study
groups. However, since a large number of patients were
lost to follow-up, the selection of patients may have
been biased. Moreover, physicians outside the study pre-
scribed antibiotics for some patients between the initial
visit and the follow-up visit. Because of the study design,
the accuracy of prescriptions during follow-up could not
be properly evaluated. Thus, our results must be inter-
preted with caution. In the absence of an algorithm to
determine how to follow the patients and act upon the
results of PCR testing, including a predefined antibiotic
management plan, the observed reduction of antibiotic
use at the initial visit may be lost by the time of follow-
u p .H o w e v e r ,o u rs t u d yr e p r e s e n t sap r o o fo fc o n c e p t
that access to a rapid etiologic diagnostic tool may affect
therapeutic decision in this setting.
The antibiotic prescription rate in our study was low.
A recent retrospective study of primary care patients in
a comparable Swedish region recorded an antibiotic pre-
scription rate of 45% for all patients with ARTIs, 60%
for patients with acute bronchitis and 16% for patients
with the ‘common cold’ [13]. The low prescription rate
in our series could be due partly to a tendency to
adhere more strictly than usual to current guidelines for
the restrictive use of antibiotics.
We detected an infectious agent in 47% of patient sam-
ples taken at the initial visit, which is in line with
previous studies in which detection rates between 43%
and 63% in adults have been described [11,31]. Detection
of a virus does not exclude concomitant bacterial infec-
tions or other noninfectious causes. This safety issue was
discussed at the beginning of our study, and physicians
were encouraged to treat bacterial complications at their
own discretion. No SAEs were reported, but because of
the relatively large number of patients lost to follow-up
and the short duration of the study, we cannot exclude
the possibility that some patients experienced late SAEs.
Patient-relevant outcomes, such as the severity of symp-
toms over time, were not recorded, which is another lim-
itation of this study. We deliberately chose not to include
such outcomes, as the primary objective of the study was
to evaluate the impact on antibiotic prescription rates at
the initial visit. This study design also reduced the
resources needed to conduct the study.
Analysis of CRP is frequently used to discriminate
viral from bacterial infections [32]. Prescription rates
increase with rising CRP levels [32,13]. In the group of
patients with CRP levels > 100 mg/L, approximately
one-third carried a respiratory virus, supporting the
need for reliable tools for the aetiologic diagnosis of
ARTIs. Distinguishing a viral from a bacterial aetiology
in ARTIs is difficult on clinical grounds alone, and the
predictive value of vital signs, CRP and X-ray findings is
low [7,8]. Procalcitonin (PCT) has been proven to be
useful in reducing antibiotic prescriptions in hospitalised
patients with lower RTIs [33,34], whereas in primary
care, the evidence of PCT for this purpose is more
ambiguous. One study of adults with ARTI (one to
twenty-eight days’ illness duration) judged to be in need
of antibiotics and treated as outpatients reported a posi-
tive effect of antibiotic use [35], but another study of
children with community-acquired pneumonia, a signifi-
cant proportion of whom were treated in the hospital,
showed a negative effect [36].
No distinct pattern of symptoms that could guide the
clinician towards a correct aetiologic diagnosis was iden-
tified in our study. Vomiting, which was the only inde-
pendent variable predicting antibiotic use, may be
interpreted as a sign of serious illness justifying antibio-
tic treatment.
Reducing the unnecessary use of antibiotics in the
treatment of patients with ARTIs is of utmost impor-
tance and cannot be accomplished by using a single
strategy. Patient- and physician-oriented educational
programmes could play an important role as previously
suggested [37]. However, these programmes do not
solve the issue of the lack of an aetiologic diagnosis,
which is important not only for adequate use of antibio-
tics but also for addressing issues such as possible com-
plications, prognosis, antiviral treatment options,
surveillance and infection control.
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In conclusion, we have shown that access to a multiplex
RT-PCR assay for the aetiologic diagnosis of ARTIs may
reduce the prescription rate of antibiotics at the initial
visit in an outpatient setting. To sustain the effect, it
seems necessary to define how to follow and manage
the patient according to the result of the test, which
warrants further investigation. We believe that the
implementation of similar methods in routine clinical
care may be a useful tool to reduce the overprescription
of antibiotics in patients with ARTIs.
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